M4
UQi007-A
General
Cell Line |
|
| hPSCreg name | UQi007-A |
| Cite as: | UQi007-A (RRID:CVCL_D6K0) |
| Alternative name(s) |
M4
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBIGi022-A-1 (SOD1 I114T correction (CBIGi022-A), IPSC0029) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis SAPi004-A (ALS III, TDP43-A382T/A382T, ALS III-TDP43-A382T/A382T) Donor diseases: Amyotrophic lateral sclerosis CBIGi049-A (IPSC0093, SOD1 I144T(CBIGi049-A)) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis UCLi004-A (RCi173, RCFB60c6) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi004-B (RCFB60c7, RCi177) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi004-C (RCi172, RCFB60c2) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia CBIGi010-A (SOD1 A4S, IPSC0014) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis CBIGi011-A (SOD1 I114T, IPSC0015) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis CBIGi014-A (VAPB A2V, IPSC0019) Donor's gene variants: VAPB, VAPB Donor diseases: Amyotrophic Lateral Sclerosis CBIGi022-A (IPSC0028, SOD1 I114T (CBIGi022-A)) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis CBIGi024-A (IPSC0031, SOD1 I144T (CBIGi024-A)) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis PFIZi013-A (RCi215, RCFB59 C9) Donor's gene variants: TARDBP, TARDBP Donor diseases: Amyotrophic lateral sclerosis |
| Last update | 13th November 2023 |
| User feedback | |
Provider |
|
| Generator | The University of Queensland (UQ) |
External Databases |
|
| BioSamples | SAMEA114591121 |
| Cellosaurus | CVCL_D6K0 |
| Wikidata | Q127384619 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46XY
Karyotyping method:
G-Banding
|
External Databases (Donor) |
|
| BioSamples | SAMEA114591122 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | RBWH HREC; University of Queensland |
| Approval number | HREC/14/QRBW/495; 2015/HE000022 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
ReLeSR
|
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: mTeSR+ or StemFlex
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| SSEA-4 |
Yes |
|
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| CXCR4 |
Yes |
| SOX17 |
Yes |
In vitro directed differentiation
| Marker | Expressed |
| NCAM1 |
Yes |
| TBXT |
Yes |
In vitro directed differentiation
| Marker | Expressed |
| Pax6 |
Yes |
| NES |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XY
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.